Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 5,277 matching trials from the live ClinicalTrials.gov search.

Filters: Gainesville, Florida Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 112
States / cities: Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, Standard fractionation RT, Accelerated fractionation radiation therapy, Conventional surgery for select patients; Drug · Radiation · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2022
U.S. locations: 195
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 55
States / cities: Birmingham, Alabama • Fullerton, California • La Palma, California + 34 more

Conditions: Autonomic Dysregulation, Anxiety, Depression, Parent-Child Relations
Interventions: Parent-Child Interaction Therapy (PCIT); Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 89 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Multiple Myeloma
Interventions: One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant, Thalidomide, Dexamethasone, Observation; Procedure · Drug · Behavioral
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Up to 70 Years
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more

Conditions: Major Depressive Disorder
Interventions: NMRA-335140; Drug
Lead sponsor: Neumora Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 904 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 126
States / cities: Huntsville, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 94 more

Conditions: Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
Interventions: VK0214, Placebo; Drug · Other
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Palo Alto, California • Gainesville, Florida • Baltimore, Maryland + 1 more

Conditions: Aging
Interventions: High-functioning older adults, Lower-functioning older adults, Young adults; Other
Lead sponsor: University of Florida; Other
Eligibility: 20 Years to 100 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Huntington's Disease
Interventions: coenzyme Q10, placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 41
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 37 more

Conditions: Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions: Cinacalcet, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 15
States / cities: Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more

Conditions: Hemophilia A
Interventions: efanesoctocog alfa (BIVV001); Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Days to 2 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 12
States / cities: Gainesville, Florida • New Orleans, Louisiana • Baltimore, Maryland + 8 more

Conditions: Endometriosis
Interventions: Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Gainesville, Florida + 22 more

Conditions: Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease
Interventions: CLBS16, Placebo; Biological
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Hollywood, Florida + 4 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 13
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: Dermatitis, Atopic
Interventions: Nanodox 1% (doxycycline monohydrate hydrogel); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: LDX 30 mg, LDX 50 mg, LDX 70 mg, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more

Conditions: COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Survey Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 37 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 72
States / cities: Birmingham, Alabama • Kingman, Arizona • Oakland, California + 50 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Prednisone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 30 more

Conditions: Bronchiectasis
Interventions: BI 1291583, Placebo matching BI 1291583; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Newport Beach, California • Sacramento, California • Gainesville, Florida + 8 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: Atorvastatin 20 mg daily for 3 months; Drug
Lead sponsor: University of Florida; Other
Eligibility: 10 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Celiac Disease
Interventions: Larazotide, Matching Placebo; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 160
States / cities: Saraland, Alabama • Scottsdale, Arizona • Tucson, Arizona + 132 more

Conditions: Delirium, Confusion
Interventions: Confusion Assessment Method, Accelerometer, Commercially available camera, Internet Pod (iPod), Cortisol Swab; Behavioral · Device · Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Traumatic Brain Injury
Interventions: SENSE device; Device
Lead sponsor: Sense Diagnostics, LLC; Industry
Eligibility: 22 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Gainesville, Florida • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 3 more

Search by objective public record fields.

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Potential Benefits of Parent Child Interaction Therapy (PCIT)

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

Study to Assess the Safety and Effectiveness of NMRA-335140-501

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN

Development of Clinical Methods to Evaluate Neural Function in Aging

Coenzyme Q10 in Huntington's Disease (HD)

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

Bay98-7196, Dose Finding / POC Study

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

ATG-GCSF in New Onset Type 1 Diabetes

Topical NanoDox® for Atopic Dermatitis

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

Intelligent Intensive Care Unit

A Study to Evaluate the SENSE Device's Ability to Detect TBI